Gene-expression signature predicts autoimmune toxicity in metastatic melanoma.

ABSTRACT:

Objectives

To identify predictive gene-expression signatures for immune-related adverse events (irAEs) in patients with melanoma treated with anti-PD-1 inhibitors, in the adjuvant therapy (AT) and first-line therapy (FLT).

Methods

This retrospective study analyzed baseline whole-blood gene expression profile from 161 patients with resected stage III or unresectable stage III-IV melanoma treated with anti-PD-1 inhibitors. RNA was extracted from baseline peripheral blood samples and profiled using the NanoString nCounter PanCancer IO 360 panel. Gene-expression signatures were identified and validated using cross-validated sparse partial least squares modeling and principal component analysis, then correlated with toxicity occurrence.

Results

A total of 223 and 186 irAEs

SUBMITTER: Mallardo D 

PROVIDER: S-EPMC12243629 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature